Show simple item record

dc.contributor.authorMoorthy, V.en_US
dc.contributor.authorDiggs, C.en_US
dc.contributor.authorFerro, S.en_US
dc.contributor.authorGood, M.en_US
dc.contributor.authorHerrera, S.en_US
dc.contributor.authorHill, Adamen_US
dc.contributor.authorImoukhuede, E.en_US
dc.contributor.authorKumar, S.en_US
dc.contributor.authorLoucq, C.en_US
dc.contributor.authorMarsh, K.en_US
dc.contributor.authorOckenhouse, C.en_US
dc.contributor.authorRichie, T.en_US
dc.contributor.authorSauerwein, R.en_US
dc.date.accessioned2017-05-03T14:54:58Z
dc.date.available2017-05-03T14:54:58Z
dc.date.issued2009en_US
dc.date.modified2011-09-22T06:52:30Z
dc.identifier.issn0264410Xen_US
dc.identifier.doi10.1016/j.vaccine.2009.07.049en_AU
dc.identifier.urihttp://hdl.handle.net/10072/40964
dc.description.abstractDevelopment and optimization of first generation malaria vaccine candidates has been facilitated by the existence of a well-established Plasmodium falciparum clinical challenge model in which infectious sporozoites are administered to human subjects via mosquito bite. While ideal for testing pre-erythrocytic stage vaccines, some researchers believe that the sporozoite challenge model is less appropriate for testing blood stage vaccines. Here we report a consultation, co-sponsored by PATH MVI, USAID, EMVI and WHO, where scientists from all institutions globally that have conducted such clinical challenges in recent years and representatives from regulatory agencies and funding agencies met to discuss clinical malaria challenge models. Participants discussed strengthening and harmonizing the sporozoite challenge model and considered the pros and cons of further developing a blood stage challenge possibly better suited for evaluating the efficacy of blood stage vaccines. This report summarizes major findings and recommendations, including an update on the Plasmodium vivax clinical challenge model, the prospects for performing experimental challenge trials in malaria endemic countries and an update on clinical safety data. While the focus of the meeting was on the optimization of clinical challenge models for evaluation of blood stage candidate malaria vaccines, many of the considerations are relevant for the application of challenge trials to other purposes.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherElsevier Ltden_US
dc.publisher.placeUnited Kingdomen_US
dc.relation.ispartofstudentpublicationNen_AU
dc.relation.ispartofpagefrom5719en_US
dc.relation.ispartofpageto5725en_US
dc.relation.ispartofissue42en_US
dc.relation.ispartofjournalVaccineen_US
dc.relation.ispartofvolume27en_US
dc.rights.retentionYen_AU
dc.subject.fieldofresearchBiological Sciences not elsewhere classifieden_US
dc.subject.fieldofresearchcode069999en_US
dc.titleReport of a Consultation on the Optimization of Clinical Challenge Trials for Evaluation of Candidate Blood Stage Malaria Vaccines, 18–19 March 2009, Bethesda, MD, USAen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.date.issued2009
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record